If the stars align we could see ourselves in an envious position. Come Q1 2024 we could be approved for a registration study for PTX-100. Hopefully by then, the market has changed its sentiment towards the biotech sector.I found this post on LinkedIn interesting from our very own Dan Shelly. FYI BioEurope is the Industries largest networking event. Pretty much speed dating for biotech companies! I would suggest it seems that Steven is hoping to leverage the success of PTX-100 to raise capital to help fund our Omnicar trials. With a bit of luck we could also see one or more partnerships for Cellpryme. He isn’t going to just let his Ferrari sit in the garage is he?
PTX Price at posting:
5.5¢ Sentiment: Buy Disclosure: Held
